Several osteoporosis medicines are given by injection rather than as tablets. They differ in how they work, how often they are given and who they are suitable for: some are given every six months, some monthly for a year and some daily for up to two years. Knowing the options makes it easier to discuss which, if any, fits your fracture risk.
Key takeaways
- Injections are not one treatment. Denosumab, romosozumab, teriparatide, abaloparatide and intravenous ibandronate each work differently and follow different schedules.
- Some protect bone and some build it. Denosumab and ibandronate slow bone breakdown; teriparatide, abaloparatide and romosozumab stimulate new bone formation.
- Two are monoclonal antibodies. Denosumab (Prolia) and romosozumab (Evenity) are antibody medicines that target specific signals controlling bone turnover.
- Bone-building courses are time-limited. They are followed by a bone-protecting medicine to keep the gains.
- Every injection needs a long-term plan. Denosumab in particular should not be stopped or delayed without a planned alternative.
Tablets such as alendronic acid remain the most common first treatment for osteoporosis in the UK. Injections are usually considered when tablets are unsuitable, not tolerated or unlikely to be enough for your level of fracture risk. Our osteoporosis treatment overview explains where medicines sit alongside nutrition, exercise and monitoring.
Why are some osteoporosis medicines given by injection?
Some medicines cannot be taken by mouth because they are proteins or peptides that would be broken down in the digestive system. Others are injected to avoid the strict instructions that go with bisphosphonate tablets, such as taking them on an empty stomach and staying upright afterwards.
An injection can also make it easier to confirm that a dose has been given. That matters because osteoporosis treatment only reduces fracture risk when it is taken consistently over time.

The main osteoporosis injections at a glance
Denosumab (Prolia): every six months
Denosumab is given as a 60 mg injection under the skin once every six months. It reduces the activity of the cells that break down bone. Our guide to denosumab side effects covers what to expect and why the schedule matters.
Romosozumab (Evenity): monthly for 12 months
Romosozumab is given as two injections under the skin once a month for 12 months, a total dose of 210 mg each month. It both increases bone formation and reduces bone breakdown. It is reserved for severe osteoporosis at high risk of fracture and is not suitable for people who have had a heart attack or stroke. See our full guide to Evenity (romosozumab).
Teriparatide: daily, for up to 24 months
Teriparatide is a bone-building medicine that you inject yourself once a day using a pen device, at a dose of 20 micrograms. Treatment is limited to 24 months. It is generally considered for people at very high fracture risk, particularly after spinal fractures.
Abaloparatide (Eladynos): daily, for up to 18 months
Abaloparatide is another daily self-injected bone-building medicine, given at 80 micrograms once a day. It is licensed in the UK for women after the menopause who are at increased risk of fracture, and the maximum treatment period is 18 months.
Ibandronate: every three months
Ibandronate is a bisphosphonate that can be given as a 3 mg injection into a vein every three months, as an alternative to tablets. Zoledronic acid is related, but it is given as a once-yearly drip rather than an injection; our bone infusion guide explains that option.
What are monoclonal antibodies for osteoporosis?
Monoclonal antibodies are laboratory-made proteins designed to attach to one specific target in the body. Two are used for osteoporosis.
- Denosumab attaches to a signal called RANKL, which switches on the cells that break down bone. Blocking it slows bone loss.
- Romosozumab attaches to sclerostin, a protein that holds back bone formation. Blocking it increases new bone formation and also reduces bone breakdown.
Because they act on bone turnover so directly, both need careful planning around what happens when the course ends. Their effects wear off and must be followed by other treatment.

Bone-building or bone-protecting: why the order matters
Bone-protecting (antiresorptive) medicines slow the rate at which bone is lost. Bone-building (anabolic) medicines stimulate new bone. UK guidance from the National Osteoporosis Guideline Group suggests that, for people at very high risk of fracture, starting with a bone-building medicine and then moving to a bone-protecting one may be the most effective sequence.
When a bone-building course finishes, a bone-protecting medicine such as alendronic acid, zoledronic acid or denosumab is started without delay. Without that step, much of the benefit can be lost. Our drug information page summarises both groups.
Who might be offered an injection?
The choice depends on your fracture history, bone density, overall fracture risk and other health conditions. An injection may be discussed if you:
- Cannot take bisphosphonate tablets because of swallowing difficulties, stomach or oesophageal problems, or difficulty following the dosing instructions
- Have had side effects or an inadequate response to tablets
- Are at very high fracture risk, for example after one or more spinal fractures or a recent major fracture
- Have kidney function that rules out some bisphosphonates
A FRAX fracture risk assessment, your DEXA result and your fracture history together guide whether treatment is needed and which kind is most appropriate.
What to check before starting
Before any osteoporosis injection, your clinician should review calcium and vitamin D levels, kidney function and your other medicines. A dental check is sensible before starting some treatments, because rare jaw complications have been reported with several bone medicines.
Most importantly, ask what happens after the course. Denosumab must not be stopped or delayed without a plan, because stopping can lead to rapid bone loss and spinal fractures. Bone-building courses have a fixed end point and need a follow-on medicine arranged in advance.
Frequently asked questions
Is there an injection for osteoporosis every six months?
Yes. Denosumab (Prolia) is given as a 60 mg injection under the skin once every six months. It is important to keep to the schedule, because delaying or stopping it without a plan can increase the risk of spinal fractures.
Are there monthly injections for osteoporosis?
Romosozumab (Evenity) is given once a month for 12 months, as two injections at each visit. It is used for severe osteoporosis at high fracture risk and is not suitable for people who have had a heart attack or stroke.
Are daily bone-building injections painful?
Teriparatide and abaloparatide use a fine needle in a pen device, similar to some diabetes pens. Most people learn to inject themselves quickly. Mild redness or discomfort at the injection site can occur.
Are injections better than tablets?
Not automatically. Tablets work well for many people. Injections are usually considered when tablets are unsuitable or not tolerated, or when fracture risk is very high. The right choice depends on your individual risk and medical history.
Can I have an injection privately?
Some osteoporosis injections can be arranged privately after a specialist assessment, subject to clinical suitability and the medicine’s licence. A consultant can explain which options apply to you and how ongoing treatment would be planned.
Discuss whether an injection is right for you
London Osteoporosis Clinic can review your fracture risk, scan results and previous treatment, and explain which options fit your situation. Arrange a consultant appointment or check the current consultation fees.
This article provides general information and does not replace advice from your own clinician. Do not start, stop or delay any osteoporosis treatment based on this article.
References and further reading
- National Osteoporosis Guideline Group. Pharmacological treatment options; accessed 18 November 2026.
- Amgen. Prolia 60 mg summary of product characteristics; accessed 18 November 2026.
- UCB Pharma. Evenity 105 mg summary of product characteristics; accessed 18 November 2026.
- Theramex. Eladynos 80 micrograms summary of product characteristics; accessed 18 November 2026.
- Royal Osteoporosis Society. Treatments and medicines; accessed 18 November 2026.